Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma

An integrated population pharmacokinetic (PPK) model was used to evaluate the effects of liver dysfunction on the pharmacokinetics (PK) of cabozantinib in patients with hepatocellular carcinoma and to determine whether clinical dosage adjustment may be necessary in this population. An integrated PPK...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Linh, Chapel, Sunny, Tran, Benjamin Duy, Lacy, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790584/
https://www.ncbi.nlm.nih.gov/pubmed/31187515
http://dx.doi.org/10.1002/jcph.1467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790584/
https://www.ncbi.nlm.nih.gov/pubmed/31187515
http://dx.doi.org/10.1002/jcph.1467

Ejemplares similares